Immunoprecise Antibodies Ltd
XTSX:IPA

Watchlist Manager
Immunoprecise Antibodies Ltd Logo
Immunoprecise Antibodies Ltd
XTSX:IPA
Watchlist
Price: 6.5 CAD 0.78% Market Closed
Market Cap: 161.4m CAD

Operating Margin
Immunoprecise Antibodies Ltd

-79%
Current
-79%
Average
3.3%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-79%
=
Operating Profit
-15m
/
Revenue
19m

Operating Margin Across Competitors

No Stocks Found

Immunoprecise Antibodies Ltd
Glance View

ImmunoPrecise Antibodies Ltd. is a therapeutic antibody discovery company, which engages in the provision of human therapeutic antibody discovery and development services. The company is headquartered in Vancouver, British Columbia and currently employs 73 full-time employees. The firm is focused on offering species-agnostic advancements, such as the B cell Select single-cell interrogation technology, DeepDisplay custom phage libraries, as well as the Abthena bispecific program. Its geographical segments include United States of America, Canada and Europe. The Company’s Antibody Discovery offers design, immunization, characterization and optimization, and preclinical services. The firm offers mammalian protein expression and purification services as stand-alone or in combination after an antibody discovery project to produce the number of antibodies that need for further work. Its mammalian rPEx platform allows the production of all kinds of proteins, including difficult-to-express proteins, Fc-fusion proteins and bispecific antibodies.

IPA Intrinsic Value
Not Available
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-79%
=
Operating Profit
-15m
/
Revenue
19m
What is the Operating Margin of Immunoprecise Antibodies Ltd?

Based on Immunoprecise Antibodies Ltd's most recent financial statements, the company has Operating Margin of -79%.

Back to Top